BCAB Profile
BioAtla, Inc. is a clinical-stage biopharmaceutical company specializing in the development of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. The company is focused on advancing innovative treatments designed to target a range of malignancies with precision and efficacy.
BioAtla’s lead product candidate, BA3011, is a conditionally active biologic (CAB) antibody-drug conjugate (ADC) aimed at treating soft tissue and bone sarcomas, non-small cell lung cancer (NSCLC), and ovarian cancer. This therapeutic leverages targeted delivery mechanisms to enhance treatment specificity and minimize off-target effects.
The company is also advancing BA3021, another CAB ADC designed for a broader spectrum of solid tumors, including NSCLC, melanoma, and ovarian cancer. Additionally, BioAtla is developing BA3071, a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody. This candidate targets multiple cancer types, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer, aiming to enhance immune response against tumor cells.
Founded in 2007 and headquartered in San Diego, California, BioAtla, Inc. is committed to advancing its proprietary technologies and clinical programs. The company’s focus on developing novel antibody-based therapies reflects its dedication to addressing unmet needs in oncology and improving patient outcomes through cutting-edge biopharmaceutical innovations.
|
